The Use of Opioids for Breakthrough Pain in Acute Palliative Care Unit by Using Doses Proportional to Opioid Basal Regimen

被引:29
作者
Mercadante, Sebastiano [1 ,2 ,3 ]
Villari, Patrizia [1 ,2 ]
Ferrera, Patrizia [1 ,2 ]
Mangione, Salvatore [3 ]
Casuccio, Alessandra [4 ]
机构
[1] La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, I-90145 Palermo, Italy
[2] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy
[3] Palliat Med Teaching, Intens Care & Emergency, Palermo, Italy
[4] Univ Palermo, Palermo, Italy
关键词
cancer pain; breakthrough-episodic pain; opioids; TRANSMUCOSAL FENTANYL CITRATE; CANCER PAIN; INTRAVENOUS MORPHINE; TITRATION; TRIAL;
D O I
10.1097/AJP.0b013e3181c4458a
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives: To determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP). Methods: In 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to re-assess the patient 15 minutes after the opioid given as a rescue medication (T15). Results: Six hundred twenty four episodes of BP were recorded during admission. Intravenous morphine (IV-MO) and oral transmucosal fentanyl (OTFC) were most frequently administered. Of 503 events available, 427 episodes were defined as successfully treated, while 76 episodes required a further administration of opioids. Pain intensity significantly decreased at T15 in all the groups (P<0.001). In 97.2% and 90.7% of cases treated with IV-MO, BP events had a reduction in pain intensity of more than 33% and 50%, respectively. In 99.2% and 97.6% patients receiving OTFC, BP events had a reduction in pain intensity of more than 33% and 50%, respectively. Discussion: This survey suggests that doses of opioids for BP proportional to the basal opioid regimen, are very effective and safe in clinical practice, regardless the opioid and modality used.
引用
收藏
页码:306 / 309
页数:4
相关论文
共 16 条
  • [1] Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
    Christie, JM
    Simmonds, M
    Patt, R
    Coluzzi, P
    Busch, MA
    Nordbrock, E
    Portenoy, RK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3238 - 3245
  • [2] Breakthrough cancer pain:: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)
    Coluzzi, PH
    Schwartzberg, L
    Conroy, JD
    Charapata, S
    Gay, M
    Busch, MA
    Chavez, J
    Ashley, J
    Lebo, D
    McCracken, M
    Portenoy, RK
    [J]. PAIN, 2001, 91 (1-2) : 123 - 130
  • [3] An observational study of oncology patients' utilization of breakthrough pain medication
    Davies, Andrew N.
    Vriens, Joanna
    Kennett, Alison
    McTaggart, Michelle
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2008, 35 (04) : 406 - 411
  • [4] Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points Making clinical trial data more understandable
    Farrar, John T.
    Dworkin, Robert H.
    Max, Mitchell B.
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 31 (04) : 369 - 377
  • [5] Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
    Farrar, JT
    Cleary, J
    Rauck, R
    Busch, M
    Nordbrock, E
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08): : 611 - 616
  • [6] Defining the clinically important difference in pain outcome measures
    Farrar, JT
    Portenoy, RK
    Berlin, JA
    Kinman, JL
    Strom, BL
    [J]. PAIN, 2000, 88 (03) : 287 - 294
  • [7] A titration strategy is needed to manage breakthrough cancer pain effectively: Observations from data pooled from three clinical trials
    Hagen, Neil A.
    Fisher, Kim
    Victorino, Charlemaigne
    Farrar, John T.
    [J]. JOURNAL OF PALLIATIVE MEDICINE, 2007, 10 (01) : 47 - 55
  • [8] Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680
  • [9] Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
    Mercadante, S.
    Villari, P.
    Ferrera, P.
    Casuccio, A.
    Mangione, S.
    Intravaia, G.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (12) : 1828 - 1833
  • [10] Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose
    Mercadante, S
    Villari, P
    Ferrera, P
    Bianchi, M
    Casuccio, A
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 27 (04) : 352 - 359